Antibiofilm and membrane-damaging potential of cuprous oxide Nanoparticles against Staphylococcus aureus with reduced susceptibility to vancomycin

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 11, 2015, Pages 6882-6890

  Singh, Avinash ^a,c   Ahmed, Asar ^b   Prasad, Kashi N ^a   Khanduja, Sonali ^a   Singh, Satyendra K ^a   Srivastava, Janmejai K ^c   Gajbhiye, Namdeo S ^b  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b INDIAN INSTITUTE OF TECHNOLOGY KANPUR   (India)

^c AMITY UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CUPROUS OXIDE; ETHIDIUM BROMIDE; PROPIDIUM IODIDE; VANCOMYCIN; ANTIINFECTIVE AGENT; COPPER; NANOPARTICLE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL MEMBRANE; BACTERIAL STRAIN; BIOFILM; CONTROLLED STUDY; FIELD EMISSION SCANNING ELECTRON MICROSCOPY; FLUORESCENCE MICROSCOPY; INHIBITORY CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARTICLE SIZE; POWDER DIFFRACTION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; UPTAKE ASSAY; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; X RAY DIFFRACTION; CHEMISTRY; DRUG EFFECTS; MICROBIAL SENSITIVITY TEST; SCANNING ELECTRON MICROSCOPY; ULTRASTRUCTURE;

ANTI-BACTERIAL AGENTS; BIOFILMS; COPPER; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; STAPHYLOCOCCUS AUREUS; VANCOMYCIN; X-RAY DIFFRACTION;

EID: 84946224341     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01440-15     Document Type: Article

References (42)

1. Yarwood JM, Bartels DJ, Volper E.M., Greenberg EP. 2004. Quorum sensing in Staphylococcus aureusbiofilms. J Bacteriol 186:1838-1850. http://dx.doi.org/10.1128/JB.186.6.1838-1850.2004.
2. Faúndez G., Troncoso M, Navarrete P., Figueroa G. 2004. Antimicrobial activity of copper surfaces against suspensions of Salmonella enterica and Campylobacter jejuni. BMC Microbiol 4:19. http://dx.doi.org/10.1186/1471-2180-4-19.
3. Howden BP, Johnson PD, Ward P.B., Stinear TP, Davies JK. 2006. Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 50:3039-3047. http://dx.doi.org/10.1128/AAC.00422-06.
4. Ren G, Hu D, Cheng E.W., Vargas-Reus MA, Reip P, Allaker RP 2009. Characterisation of copper oxide nanoparticles for antimicrobial applications. Int J Antimicrob Agents 33:587-590. http://dx.doi.org/10.1016/j.ijantimicag.2008.12.004.
5. Howden BP, Ward PB, Charles P.G., Korman TM, Fuller A, du Cros P, Grabsch EA, Roberts S.A., Robson J., Read K, Bak N, Hurley J., Johnson PD, Morris AJ, Mayall BC, Grayson ML 2004. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 38:521-528. http://dx.doi.org/10.1086/381202.
6. Vuong C, Saenz HL, Gotz F, Otto M. 2000. Impact of the agr quorumsensing system on adherence to polystyrene in Staphylococcus aureus. J Infect Dis 182:1688-1693. http://dx.doi.org/10.1086/317606.
7. Sakoulas G, Eliopoulos GM, Moellering R.C., Jr, Novick RP, Venkataraman L, Wennersten C, DeGirolami PC, Schwaber MJ, Gold HS. 2003. Staphylococcus aureus accessory gene regulator (agr) group II: is there a relationship to the development of intermediate-level glycopeptide resistance? J Infect Dis 187:929-938. http://dx.doi.org/10.1086/368128.
8. Dunne WM, Jr. 2002. Bacterial adhesion: seen any good biofilms lately? Clin Microbiol Rev 15:155-166. http://dx.doi.org/10.1128/CMR.15.2.155-166.2002.
9. Bagga B, Reddy AK, Garg P. 2010. Decreased susceptibility to quinolones in methicillin-resistant Staphylococcus aureus isolated from ocular infectionsata tertiary eye care centre. Br J Ophthalmol 94:1407-1408. http://dx.doi.org/10.1136/bjo.2010.179747.
10. Howden BP, Davies JK, Johnson P.D., Stinear TP, Grayson ML. 2010. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev 23:99-139. http://dx.doi.org/10.1128/CMR.00042-09.
11. Singh A, Prasad KN, Misra R, Rahman M., Singh SK, Rai RP, Tripathi A, Srivastava JK 29 May 2015. Increasing trend of heterogeneous vancomycin intermediate Staphylococcus aureus in a tertiary care center of northern India. Microb Drug Resist http://online.liebertpub.com/doi/abs/10.1089/mdr.2015.0004.
12. Maor Y, Rahav G, Belausov N., Ben-David D, Smollan G, Keller N. 2007. Prevalence and characteristics of heteroresistant vancomycinintermediate Staphylococcus aureus bacteremia in a tertiary care center. J Clin Microbiol 45:1511-1514. http://dx.doi.org/10.1128/JCM.01262-06.
13. Chen J, Han CM, Lin X.W., Tang ZJ, Su SJ. 2006. Effect of silver nanoparticle dressing on second degree burn wound. Zhonghua Wai Ke Za Zhi 44:50-52. (In Chinese.)
14. Stoimenov PK, Klinger RL, Marchin GLM, Klabunde KJ. 2002. Metal oxide nanoparticles as bactericidal agents. Langmuir 18:6679-6686. http://dx.doi.org/10.1021/la0202374.
15. Usman MS, El Zowalaty ME, Shameli K, Zainuddin N, Salama M., Ibrahim NA. 2013. Synthesis, characterization, and antimicrobial properties of copper nanoparticles. Int J Nanomed 8:4467-4479. http://dx.doi.org/10.2147/IJN.S50837.
16. 2O nanoparticles on E. coli synthesized from Tridax procumbens leaf extract and surface coating with polyaniline. Dig J Nanomater Biostruct 7:833-839.
17. Huang LN, Wang HT, Wang Z.B., Mitra A. 2002. Cuprite nanowires by electrodeposition from lyotropic reverse hexagonal liquid crystalline phase. Chem Mater 14:876-880. http://dx.doi.org/10.1021/cm010819r.
18. Ruparelia JP, Chatterjee AK, Duttagupta S.P., Mukherji S. 2008. Strain specificity in antimicrobial activity of silver and copper nanoparticles. Acta Biomater 4:707-716. http://dx.doi.org/10.1016/j.actbio.2007.11.006.
19. Seigfried MJ, Choi KS 2005. Directing the architecture of cuprous oxide crystals during electrochemical growth. Angew Chem 117:3282-3287. http://dx.doi.org/10.1002/ange.200463018.
20. 2O nano-octahedra at room temperature. J Solid State Chem 184:2209-2214. http://dx.doi.org/10.1016/j.jssc.2011.05.058.
21. Karlsson HL, Cronholm P, Hedberg Y., Tornberg M, De Battice L, Svedhem S, Wallinder IO 2013. Cell membrane damage and protein interaction induced by copper containing nanoparticles - importance of the metal release process. Toxicology 313:59-69. http://dx.doi.org/10.1016/j.tox.2013.07.012.
22. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 9th ed. Approved standard M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
23. Wei GX, Campagna AN, Bobek LA 2006. Effect of MUC7 peptides on the growth of bacteria and on Streptococcus mutans biofilm. J Antimicrob Chemother 57:1100-1109. http://dx.doi.org/10.1093/jac/dkl120.
24. Cox SD, Mann CM, Markham J.L., Gustafson JE, Warmington JR, Wyllie SG. 2001. Determining the antimicrobial actions of tea tree oil. Molecules 6:87-91. http://dx.doi.org/10.3390/60100087.
25. Lowry OH, Rosebrough NJ, Farr A.L., Randall RJ. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
26. Wiczling P, Krzyzanski W. 2008. Flow cytometric assessment of homeostatic aging of reticulocytes in rats. Exp Hematol 36:119-127. http://dx.doi.org/10.1016/j.exphem.2007.09.002.
27. Carson CF, Mee BJ, Riley TV 2002. Mechanism of action of Melaleuca alternifolia (tea tree) oil on Staphylococcus aureus determined by time-kill, lysis, leakage, and salt tolerance assays and electron microscopy. Antimicrob Agents Chemother 46:1914-1920. http://dx.doi.org/10.1128/AAC.46.6.1914-1920.2002.
28. Laloy J, Valentine Minet, Alpan L, Mullier F., Beken S, Toussaint O, Lucas S., Dogné J-M. 2014. Impact of silver nanoparticles on haemolysis, platelet function and coagulation. Nanobiomedicine 1:4. http://dx.doi.org/10.5772/59346.
29. Kawahara K, Tsuruda K, Morishita M., Uchida M. 2000. Antibacterial effect of silver-zeolite on oral bacteria under anaerobic conditions. Dent Mater 16:452-455. http://dx.doi.org/10.1016/S0109-5641(00)00050-6.
30. Donlan RM, Murga R, Bell M., Toscano CM, Carr JH, Novicki TJ, Zuckerman C, Corey L.C., Miller JM. 2001. Protocol for detection of biofilms on needleless connectors attached to central venous catheters. J Clin Microbiol 39:750-753. http://dx.doi.org/10.1128/JCM.39.2.750-753.2001.
31. Kang S, Pinault M, Pfefferle L.D., Elimelech M. 2007. Single-walled carbon nanotubes exhibit strong antimicrobial activity. Langmuir 23: 8670-8673. http://dx.doi.org/10.1021/la701067r.
32. Casapao AM, Leonard SN, Davis S.L., Lodise TP, Patel N, Goff DA, Laplante K.L., Potoski BA, Rybak MJ. 2013. Clinical outcomes in patients with heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) bloodstream infection. Antimicrob Agents Chemother 57:4252-4259. http://dx.doi.org/10.1128/AAC.00380-13.
33. Sun H, Choy TS, Zhu D.R., Yam WC, Fung YS. 2009. Nano-silvermodified PQC/DNA biosensor for detecting E. coli in environmental water. Biosens Bioelectron 24:1405-1410. http://dx.doi.org/10.1016/j.bios.2008.08.008.
34. Sondi I, Salopek-Sondi B. 2004. Silver nanoparticles as antimicrobial agent: a case study on E. coli as a model for Gram-negative bacteria. J Colloid Interface Sci 275:177-182. http://dx.doi.org/10.1016/jjcis.2004.02.012.
35. Graham JE, Wilkinson BJ 1992. Staphylococcus aureus osmoregulation: roles for choline, glycine betaine, proline, and taurine. J Bacteriol 174: 2711-2716.
36. Hiramatsu K, Cui L, Kuroda M., Ito T. 2001. The emergence and evolution of methicillin-resistant Staphylococcus aureus. Trends Microbiol 9:486-493. http://dx.doi.org/10.1016/S0966-842X(01)02175-8.
37. Gupta VK, Verma S, Gupta S., Singh A, Pal A, Srivastava S.K., Srivastava PK, Singh SC, Darokar MP. 2012. Membrane-damaging potential of natural L-(-)-usnic acid in Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 31:3375-3383. http://dx.doi.org/10.1007/s10096-012-1706-7.
38. Kim S, Lee H, Lee S., Yoon Y, Choi KH. 2015. Antimicrobial action of oleanolic acid on Listeria monocytogenes, Enterococcus faecium, and Enterococcus faecalis. PLoS One 10:e0118800. http://dx.doi.org/10.1371/journal.pone.0118800.
39. Brehm-Stecher B.F., Johnson EA 2003. Sensitization of Staphylococcus aureus and Escherichia coli to antibiotics by the sesquiterpenoids nerolidol, farnesol, bisabolol, and apritone. Antimicrob Agents Chemother 47: 3357-3360. http://dx.doi.org/10.1128/AAC.47.10.3357-3360.2003.
40. Okuda K, Zendo T, Sugimoto S., Iwase T, Tajima A, Yamada S., Sonomoto K, Mizunoe Y. 2013. Effects of bacteriocins on methicillinresistant Staphylococcus aureus biofilm. Antimicrob Agents Chemother 57:5572-5579. http://dx.doi.org/10.1128/AAC.00888-13.
41. Werth BJ, Vidaillac C, Murray K.P., Newton KL, Sakoulas G, Nonejuie P, Pogliano J., Rybak MJ. 2013. Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycinintermediate Staphylococcus aureus (VISA) and heterogeneous VISA. Antimicrob Agents Chemother 57:2376-2379. http://dx.doi.org/10.1128/AAC.02354-12.
42. Lunde CS, Rexer CH, Hartouni S.R., Axt S., Benton BM. 2010. Fluorescence microscopy demonstrates enhanced targeting of telavancin to the division septum of Staphylococcus aureus. Antimicrob Agents Chemother 54:2198-2200. http://dx.doi.org/10.1128/AAC.01609-09.